PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 47,016 shares, a decline of 76.6% from the August 15th total of 200,670 shares. Currently, 8.2% of the company’s stock are short sold. Based on an average daily trading volume, of 74,557 shares, the short-interest ratio is currently 0.6 days.

PainReform Price Performance

NASDAQ:PRFX traded down $0.07 during mid-day trading on Friday, reaching $0.86. The stock had a trading volume of 88,064 shares, compared to its average volume of 106,769. The business’s 50 day moving average is $1.08 and its 200 day moving average is $1.74. PainReform has a fifty-two week low of $0.85 and a fifty-two week high of $7.95. The stock has a market cap of $748,287.00, a P/E ratio of -0.00 and a beta of 1.05.

PainReform (NASDAQ:PRFX) last issued its quarterly earnings data on Thursday, September 3rd. The company reported ($1.13) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter.

Analysts Set New Price Targets

A number of equities research analysts have commented on PRFX shares. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research report on Friday, July 17th. Wall Street Zen upgraded PainReform to a “sell” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.